View:

Download DOC

Download PDF

Download XLS

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)*

Precigen, Inc. (Name of Issuer)

Common Stock (Title of Class of Securities)

(CUSIP Number)

06/09/2026 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Ares Trading SA
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization SWITZERLAND
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 17,467,152.00 6 Shared Voting Power 0.00 7 Sole Dispositive Power 17,467,152.00 8 Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 17,467,152.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 4.9 %
12	Type of Reporting Person (See Instructions) CO

Comment for Type of Reporting Person:  Note to Row 11: This percentage is based upon a denominator of 358,035,247 shares of Common Stock outstanding as of July 31, 2026 as reported on the cover page of the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 filed with the Securities and Exchange Commission on August 4, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Merck Serono SA, Aubonne, Switzerland, an affiliate of Merck KGaA, Darmstadt
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization SWITZERLAND
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 17,467,152.00 6 Shared Voting Power 0.00 7 Sole Dispositive Power 17,467,152.00 8 Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 17,467,152.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 4.9 %
12	Type of Reporting Person (See Instructions) CO

Comment for Type of Reporting Person:  Note to Row 11: This percentage is based upon a denominator of 358,035,247 shares of Common Stock outstanding as of July 31, 2026 as reported on the cover page of the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 filed with the Securities and Exchange Commission on August 4, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Merck KGaA, Darmstadt, Germany
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization GERMANY
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 17,467,152.00 6 Shared Voting Power 0.00 7 Sole Dispositive Power 17,467,152.00 8 Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 17,467,152.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 4.9 %
12	Type of Reporting Person (See Instructions) CO

Comment for Type of Reporting Person:  Note to Row 11: This percentage is based upon a denominator of 358,035,247 shares of Common Stock outstanding as of July 31, 2026 as reported on the cover page of the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 filed with the Securities and Exchange Commission on August 4, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons E. Merck KG, Darmstadt Germany
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization GERMANY
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 17,467,152.00 6 Shared Voting Power 0.00 7 Sole Dispositive Power 17,467,152.00 8 Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 17,467,152.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 4.9 %
12	Type of Reporting Person (See Instructions) CO

Comment for Type of Reporting Person:  Note to Row 11: This percentage is based upon a denominator of 358,035,247 shares of Common Stock outstanding as of July 31, 2026 as reported on the cover page of the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 filed with the Securities and Exchange Commission on August 4, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Precigen, Inc.
(b)	Address of issuer's principal executive offices: 20374 Seneca Meadows Parkway, Germantown, Maryland, 20876
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed by each of the following persons (each, a "Reporting Person" and together, the "Reporting Persons"): Ares Trading SA Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany Merck KGaA, Darmstadt, Germany E.Merck KG, Darmstadt, Germany The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k)(l) of the Securities Exchange Act of 1934, as amended.
(b)	Address or principal business office or, if none, residence: Ares Trading SA: Zone Industrielle de l'Outriettaz, 1170 Aubonne, Switzerland Merck Serono SA, Aubonne, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany Merck KGaA: Frankfurter Strasse 250, 64293 Darmstadt, Germany E. Merck KG: Emanuel-Merck-Platz 1, 64293 Darmstadt, Germany
(c)	Citizenship: The Reporting Persons Ares Trading SA and Merck Serono SA Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany are organized in Switzerland. The Reporting Persons Merck KGaA and E. Merck KG are organized in Darmstadt, Germany.
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),        please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 17,467,152
(b)	Percent of class: 4.9%  %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 17,467,152
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 17,467,152
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE
	After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Ares Trading SA

Signature: /s/ Florence Jolidon Name/Title: Florence Jolidon / Board Member Date: 08/07/2026

Signature: /s/ Prisca von Ballmoos Name/Title: Prisca von Ballmoos / Registered Proxy Date: 08/06/2026

Merck Serono SA, Aubonne, Switzerland, an affiliate of Merck KGaA, Darmstadt

Signature: /s/ Florence Jolidon Name/Title: Florence Jolidon / Board Member Date: 08/07/2026

Signature: /s/ Prisca von Ballmoos Name/Title: Prisca von Ballmoos / Registered Proxy Date: 08/06/2026

Merck KGaA, Darmstadt, Germany

Signature: /s/ Katharina Kneisel Name/Title: Katharina Kneisel / Registered Proxy Date: 08/07/2026

Signature: /s/ Abhira Gonge Name/Title: Abhira Gonge / Registered Proxy Date: 08/06/2026

E. Merck KG, Darmstadt Germany

Signature: /s/ Kristin Eibisch Name/Title: Kristin Eibisch / Attorney in Fact Date: 08/06/2026

Signature: /s/ Clemens Canel Name/Title: Clemens Canel / Attorney in Fact Date: 08/06/2026

Comments accompanying signature:  Power of attorney for signatories signing as Attorney in Fact included in Exhibit 99.1 page 2

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement

Exhibit 99.1

JOINT FILING AGREEMENT

Pursuant to Rule 13d-1(k)(1) of the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the joint filing on behalf of each of them of the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the share capital of Precigen, Inc.

This Joint Filing Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.

Dated: Darmstadt, 6 August 2026

POWER OF ATTORNEY

E. Merck KG, Darmstadt, Germany (the “Company”), hereby makes, constitutes and appoints each of Dr. Matthias Müllenbeck, MBA, Jens Eckhardt, Kristin Eibisch, Abhira Gonge, Clemens Canel, or any of them acting singly, and with full power of substitution and re-substitution, the Company’s true and lawful attorney-in-fact (each of such persons and their substitutes being referred to herein as the “Attorney-in-Fact”), with full power to act for the Company and in the Company’s name, place and stead, to: (i) sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of E. Merck KG, Darmstadt, Germany, pursuant to Section 13 or 16 of the Securities Exchange Act of 1934, as amended, and any and all regulations promulgated thereunder, (ii) file the same (including any amendments thereto), with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission and (iii) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such Attorney-in-Fact, may be of benefit to, in the best interest of, or legally required by, the Company, it being understood that the documents executed by such Attorney-in-Fact on behalf of the Company pursuant to this power of attorney shall be in such form and shall contain such terms and conditions as such Attorney-in-Fact may approve in such Attorney-in-Fact’s discretion, granting unto said Attorney-in-Fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate.

The Company hereby grants to the Attorney-in-Fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present with full power of substitution or revocation, hereby ratifying and confirming all that such Attorney-in-Fact or such Attorney-in-Fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.

This Power of Attorney shall remain in full force and effect until July 31, 2027 unless earlier revoked by the Company in a signed writing delivered to the Attorney-in-Fact, or, in respect of any Attorney-in-Fact named herein, until such person ceases to be an employee of Merck KGaA or one of its affiliates.

IN WITNESS WHEREOF, the undersigned have executed this Power of Attorney as of July 30, 2026.